AGE - AgeX Therapeutics Inc Stock Price, Fair Value and News

8.30USD-0.60 (-6.74%)Market Closed

Market Summary

USD8.30-0.60

Market Closed

-6.74%

AGE Stock Price

View Fullscreen

AGE RSI Chart

AGE Valuation

Market Cap

20.8M

Price/Earnings (Trailing)

-1.4

Price/Sales (Trailing)

146.17

EV/EBITDA

1.04

Price/Free Cashflow

-2.66

AGE Price/Sales (Trailing)

AGE Profitability

Operating Margin

71.83%

EBT Margin

10422.54%

Return on Equity

-270.67%

Return on Assets

-123.72%

Free Cashflow Yield

-37.58%

AGE Fundamentals

AGE Revenue

Revenue (TTM)

142.0K

Rev. Growth (Yr)

600%

Rev. Growth (Qtr)

-16.42%

AGE Earnings

Earnings (TTM)

-14.8M

Earnings Growth (Yr)

-27.86%

Earnings Growth (Qtr)

36.01%

Breaking Down AGE Revenue

Last 7 days

-20.3%

Last 30 days

-28.2%

Last 90 days

-42.8%

Trailing 12 Months

-60.6%

How does AGE drawdown profile look like?

AGE Financial Health

Current Ratio

0.13

AGE Investor Care

Shares Dilution (1Y)

1.55%

Diluted EPS (TTM)

-13.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	39.0K	36.0K	71.3K	142.0K
2022	116.5K	89.0K	61.5K	34.0K
2021	306.8K	252.5K	198.3K	144.0K
2020	1.9M	1.5M	940.5K	361.0K
2019	1.5M	1.5M	1.5M	1.7M
2018	1.4M	1.4M	1.4M	1.4M
2017	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of AgeX Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 14, 2023	juvenescence ltd	gifted	-	-	-16,447,500	-
Mar 11, 2023	west michael d	sold (taxes)	-625	0.59	-1,060	chief executive officer
Mar 11, 2023	west michael d	acquired	-	-	3,125	chief executive officer
Dec 11, 2022	west michael d	sold (taxes)	-637	0.59	-1,081	chief executive officer
Dec 11, 2022	west michael d	acquired	-	-	3,125	chief executive officer
Sep 11, 2022	west michael d	sold (taxes)	-607	0.5623	-1,081	chief executive officer
Sep 11, 2022	west michael d	acquired	-	-	3,125	chief executive officer
Jun 11, 2022	west michael d	sold (taxes)	-832	0.7702	-1,081	chief executive officer
Jun 11, 2022	west michael d	acquired	-	-	3,125	chief executive officer
Mar 11, 2022	west michael d	sold (taxes)	-886	0.6923	-1,281	chief executive officer

Which funds bought or sold AGE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 02, 2024	Sigma Planning Corp	sold off	-100	-110,274	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	sold off	-100	-28.00	-	-%
Apr 30, 2024	Avior Wealth Management, LLC	sold off	-100	-11.00	-	-%
Apr 26, 2024	Planning Capital Management Corp	sold off	-100	-4.00	-	-%
Apr 25, 2024	Lindbrook Capital, LLC	sold off	-100	-66.00	-	-%
Apr 19, 2024	ALBION FINANCIAL GROUP /UT	sold off	-100	-118	-	-%
Apr 18, 2024	Piscataqua Savings Bank	sold off	-100	-380	-	-%
Apr 12, 2024	Pacifica Partners Inc.	sold off	-100	-99.00	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.48	-204,745	270,176	-%

Are Funds Buying or Selling AGE?

Are funds buying AGE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AGE

No. of Funds

Unveiling AgeX Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 03, 2024	moreadith randall	6.8%	614,961	SC 13D
Mar 26, 2024	juvenescence ltd	81.4%	2,667,457	SC 13D/A
Mar 07, 2024	juvenescence ltd	81.1%	92,399,774	SC 13D/A
Feb 14, 2024	juvenescence ltd	81.0%	91,473,463	SC 13D/A
Feb 05, 2024	juvenescence ltd	80.6%	89,308,271	SC 13D/A
Jan 17, 2024	juvenescence ltd	80.4%	88,488,113	SC 13D/A
Jan 09, 2024	juvenescence ltd	80.2%	86,925,820	SC 13D/A
Dec 13, 2023	juvenescence ltd	80.4%	88,312,009	SC 13D/A
Nov 16, 2023	juvenescence ltd	79.4%	82,705,949	SC 13D/A
Nov 01, 2023	juvenescence ltd	79.2%	81,995,827	SC 13D/A

Recent SEC filings of AgeX Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 03, 2024	8-K	Current Report
May 03, 2024	S-1	Initial Public Offering
Apr 17, 2024	3	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	8-K	Current Report
Apr 04, 2024	4	Insider Trading
Apr 03, 2024	SC 13D	13D - Major Acquisition
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading

Peers (Alternatives to AgeX Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

AgeX Therapeutics Inc News

Latest updates

AgeX Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-16.4%	56,000	67,000	38,000	9,000	10,000	8,000	9,000	12,000	5,000	17,750	30,500	43,250	56,000	52,333	48,667	45,000	515,000	549,000	411,000	380,000	388,000
Cost Of Revenue	-97.0%	1,000	33,000	-	5,000	1,000	1,000	5,000	6,000	1,000	1,000	2,000	13,000	3,000	5,000	17,000	3,000	1,000	79,000	49,000	53,000	63,000
Gross Profit	61.8%	55,000	34,000	-	4,000	9,000	7,000	4,000	6,000	4,000	26,000	22,000	24,000	53,000	153,000	52,000	42,000	88,000	470,000	362,000	327,000	325,000
Operating Expenses	51.3%	3,615,000	2,390,000	-	1,890,000	2,167,000	1,789,000	1,554,000	1,597,000	2,056,000	1,893,000	1,696,000	2,229,000	2,346,000	2,480,000	2,449,000	2,410,000	3,096,000	6,633,000	3,641,000	3,769,000	-3,447,000
S&GA Expenses	58.1%	3,433,000	2,172,000	-	1,730,000	1,993,000	1,581,000	1,392,000	1,338,000	1,660,000	1,517,000	1,421,000	1,748,000	2,022,000	1,575,000	1,796,000	1,475,000	1,875,000	1,717,000	2,194,000	2,119,000	2,109,000
R&D Expenses	-16.5%	182,000	218,000	-	160,000	174,000	208,000	162,000	259,000	396,000	376,000	275,000	481,000	324,000	905,000	653,000	935,000	1,221,000	1,469,000	1,447,000	1,650,000	1,338,000
EBITDA Margin	532.9%	138	-32.04	-77.54	-153	-140	-176	-108	-76.73	-65.26	-47.84	-44.64	-37.30	-30.56	-28.85	-	-	-	-	-	-	-
Interest Expenses	-100.9%	-28,000	3,036,000	-	792,000	1,100,000	978,000	923,000	863,000	571,000	295,000	285,000	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	18,000	54,000	3,000	73,000
Earnings Before Taxes	-	-	-	-	-	-	18,261,000	-2,436,000	-2,618,000	-2,707,000	-2,262,000	-1,955,000	-2,475,000	-1,993,000	-3,137,000	-2,524,000	-2,432,000	-3,033,000	-2,723,000	-3,223,000	-3,152,000	-3,138,000
EBT Margin	210.9%	104	-93.97	-140	-278	-257	-294	-162	-107	-80.68	-60.31	-48.22	-40.11	-32.88	-30.82	-	-	-	-	-	-	-
Net Income	36.0%	-3,456,000	-5,401,000	-	-2,669,000	-3,277,000	-2,703,000	-2,435,000	-2,618,000	-2,706,000	-2,158,000	-1,955,000	-2,474,000	-2,088,000	-2,446,000	-2,543,000	-2,689,000	-3,187,000	-2,711,000	-3,221,000	-3,089,000	-3,133,000
Net Income Margin	20.9%	-104	-131	-155	-307	-282	-307	-161	-106	-79.77	-60.24	-45.21	-37.83	-31.84	-30.10	-	-	-	-	-	-	-
Free Cashflow	-10.1%	-2,052,000	-1,864,000	-2,019,000	-2,019,000	-1,865,000	-1,321,000	-1,236,000	-1,746,000	-1,636,000	-1,647,000	-1,884,000	-1,694,000	-2,630,000	-1,620,000	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-2.0%	11,965	12,210	12,277	12,531	3,241	2,008	2,579	2,716	3,154	2,427	2,541	3,160	3,925	4,203	4,757	5,092	7,442	8,183	10,257	12,321	10,671
Current Assets	-33.9%	754	1,141	1,350	1,747	2,453	1,187	1,725	1,829	2,234	1,475	1,556	2,142	2,283	1,929	2,104	2,072	4,054	4,690	6,680	9,648	7,853
Cash Equivalents	-13.1%	345	397	261	280	645	466	702	448	584	731	615	809	527	1,107	1,033	468	2,352	3,768	5,813	8,586	6,707
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	442	681	898	1,126	1,010	951	84.00	90.00
Liabilities	69.5%	6,607	3,897	34,573	32,536	20,556	17,157	15,841	14,307	15,029	12,405	10,835	9,263	9,321	7,949	6,879	5,467	4,825	3,240	2,850	2,294	2,440
Current Liabilities	84.6%	5,914	3,204	24,505	22,525	10,078	8,809	9,085	10,099	8,967	6,598	5,271	3,929	5,357	4,854	4,713	5,467	3,297	2,907	2,629	-	2,440
Shareholder's Equity	-	5,469	-	-	-	-17,315	-	-	-	-11,875	-	-	-	-	-	-	-	2,617	4,943	7,407	10,027	8,231
Retained Earnings	-2.7%	-131,000	-127,557	-122,200	-119,487	-116,210	-113,507	-111,072	-108,500	-105,748	-103,590	-101,600	-99,161	-97,073	-94,627	-92,084	-89,395	-86,208	-83,497	-80,276	-77,187	-74,054
Additional Paid-In Capital	36.5%	136,482	100,017	99,977	99,589	98,998	98,399	97,850	96,903	93,912	93,650	93,379	93,095	91,810	90,880	89,555	88,608	88,353	87,758	86,975	86,480	81,499
Shares Outstanding	1.5%	1,079	1,063	1,063	1,063	1,079	1,063	1,062	1,062	1,062	1,060	1,062	1,062	1,055	-	-	-	-	-	-	-	-
Minority Interest	-1.8%	-111	-109	-121	-111	-103	-45.00	-44.00	-44.00	-43.00	-42.00	-42.00	-41.00	-280	-95.00	322	364	399	604	660	706	784
Float	-	-	-	18,700	-	-	-	12,100	-	-	-	32,500	-	-	-	19,600	-	-	-	56,400	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-10.1%	-2,052	-1,864	-2,019	-1,865	-1,321	-1,236	-1,746	-1,636	-1,647	-1,884	-1,694	-2,630	-1,620	-1,889	-2,244	-2,064	-2,411	-2,372	-2,759	-2,618	-2,046
Share Based Compensation	1157.5%	503	40.00	35.00	70.00	114	209	198	239	263	272	286	178	178	227	252	252	420	491	515	481	748
Cashflow From Investing	-	-	-	-	-10,000	-	-	-	-	-	-	-	666	-	-12.00	-4.00	-4.00	-295	-157	94.00	-3.00	3.00
Cashflow From Financing	0%	2,000	2,000	2,000	11,500	1,500	1,000	2,000	1,500	1,500	2,000	1,500	2,246	992	1,977	2,807	185	1,287	487	-9.00	4,500	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AGE Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
REVENUES
Total revenues	$ 142	$ 34
Cost of sales	(40)	(13)
Gross profit	102	21
OPERATING EXPENSES
Research and development	734	1,025
General and administrative	9,328	5,971
Total operating expenses	10,062	6,996
Gain on disposition of fixed assets	73
Loss from operations	(9,887)	(6,975)
OTHER EXPENSE, NET
Interest expense, net	(4,900)	(3,335)
Change in fair value of warrants	(35)	(225)
Other income, net	11	13
Total other expense, net	(4,924)	(3,547)
NET LOSS	(14,811)	(10,522)
Net loss attributable to noncontrolling interest	8	60
NET LOSS ATTRIBUTABLE TO AGEX	$ (14,803)	$ (10,462)
NET LOSS PER COMMON SHARE:
BASIC	$ (13.72)	$ (9.70)
DILUTED	$ (13.72)	$ (9.70)
WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:
BASIC	1,079	1,079
DILUTED	1,079	1,079
Grant Revenues [Member]
REVENUES
Total revenues	$ 77
Other Revenues [Member]
REVENUES
Total revenues	$ 65	$ 34

AGE Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 345	$ 645
Accounts and grants receivable, net	57	4
Prepaid expenses and other current assets	352	1,804
Total current assets	754	2,453
Restricted cash	50	50
Intangible assets, net	607	738
Convertible note receivable	10,554
TOTAL ASSETS	11,965	3,241
Current liabilities:
Accounts payable and accrued liabilities	2,176	1,034
Loans due to Juvenescence, net of debt issuance costs, current portion	3,672	7,646
Warrant liability		180
Insurance premium liability and other current liabilities		1,077
Total current liabilities	5,914	10,078
Loans due to Juvenescence, net of debt issuance costs, net of current portion	693	10,478
TOTAL LIABILITIES	6,607	20,556
Commitments and contingencies (Note 10)
Stockholders’ equity/(deficit):
Preferred stock value
Common stock, $0.0001 par value, 200,000 shares authorized, 1,079 shares issued and outstanding
Additional paid-in capital	136,482	98,998
Accumulated deficit	(131,013)	(116,210)
Total AgeX Therapeutics, Inc. stockholders’ equity/(deficit)	5,469	(17,212)
Noncontrolling interest	(111)	(103)
Total stockholders’ equity/(deficit)	5,358	(17,315)
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY/(DEFICIT)	11,965	3,241
Series A Preferred Stock [Member]
Stockholders’ equity/(deficit):
Preferred stock value
Series B Preferred Stock [Member]
Stockholders’ equity/(deficit):
Preferred stock value
Related Party [Member]
Current liabilities:
Related party payables, net	$ 66	$ 141

About AgeX Therapeutics Inc

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.

CEO	Dr. Joanne M. Hackett Ph.D.
WEBSITE	agexinc.com
INDUSTRY	Biotechnology
EMPLOYEES	5

AgeX Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for AgeX Therapeutics Inc? What does AGE stand for in stocks?

AGE is the stock ticker symbol of AgeX Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AgeX Therapeutics Inc (AGE)?

As of Fri May 03 2024, market cap of AgeX Therapeutics Inc is 20.76 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGE stock?

You can check AGE's fair value in chart for subscribers.

What is the fair value of AGE stock?

You can check AGE's fair value in chart for subscribers. The fair value of AgeX Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AgeX Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AGE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AgeX Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AGE is over valued or under valued. Whether AgeX Therapeutics Inc is cheap or expensive depends on the assumptions which impact AgeX Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGE.

What is AgeX Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, AGE's PE ratio (Price to Earnings) is -1.4 and Price to Sales (PS) ratio is 146.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGE PE ratio will change depending on the future growth rate expectations of investors.